Dr.Suprio Kumar Datta, D21551
AIM-To compare the effect of intavitreal bevacizumab with triamcinolone acetonide in treatment of diabetic macular edema with respect to visual outcome and macular thickness.
METHODS-A total of 60 patients with diabetic macular edema were included in this study & randomized to two equal groups. 1 group received 3 injections of bevacizumab in monthly intervals.The 2nd group received 3 injections of triamcinolone. Functional & anatomic results were evaluated monthly.
RESULTS-Baseline best corrected visual acuity (BCVA) was 0.80 logMAR & central retinal subfield thickness (CSRT) was 515μm in bevacizumab group & 0.78 logMAR & 485μm CSRT in triamcinolone group.After 12 months, BCVA improved to 0.20 logMAR (bevacizumab) & 271μm CRST & 0.36 logMAR (triamcinolone) & 298 μm CSRT.
CONCLUSION-At month 12, BCVA was superior in the bevacizumab than in the triamcinolone group. This may be related to cataract development following steroid treatment, as well as to substance-specific mechanisms.
Leave a Comment